On March 12, in the office building of the National University Biomedical Regional Technology Transfer and Transformation Center (Nanjing, Jiangsu Province) (hereinafter referred to as the "Nanjing Biomedical Sub-center"), Gulou Hospital, affiliated to the Medical College of Nanjing University, launched an incubation project, the Gulou Hospital.Inox Bio's developers are utilizing flow cytometry in their experiments.
As a start-up company, Innos Biologics focuses on the R&D attack of cell sorting, culture and gene editing technology in immunization products. "Our R&D requires a flow cytometer and a specialized cell room, which is not only costly but also lengthy for enterprises to build on their own.The Nanjing Biomedical Subcenter provided us with experimental space and equipment, which significantly reduced the entrepreneurial risk of the project."Dr. Yafeng Wang, head of Inox Bio, said.
Billions of dollars invested in equipment
Providing "hardcore support"
The Nanjing Biomedical Sub-center, which was listed on December 27 last year, is aiming at serving the technology transfer and transformation of national universities and colleges, so that more biomedical "source innovations" can be transformed in Nanjing, and high "research value" can bring about high output value.
In the field of biomedicine, the development of new drugs is a systematic project, which needs to go through countless trials and validation, and requires high-precision equipment as support. In the mass spectrometry center of Nanjing Biomedical Subcenter, there are more than 40 high-resolution mass spectrometry detectors. Lv Xingxiang, a staff member of the sub-center, introduced that the price of each mass spectrometry detector is as high as millions of dollars, which is a necessary equipment for the transformation of scientific research for university teachers and enterprises.
"In the Nanjing Biomedical Subcenter, university teachers and enterprises can not only make appointments to rent equipment, but also enjoy professional services throughout the whole process of drug R&D. For example, at a certain stage of drug R&D, we provide support for experimental data, which makes project transformation more convenient."Lv Xingxiang said.
Operation of more than three months to build a more complete equipment and service platform, Nanjing Biomedical Sub-center of the construction of the efficient.
"Previously, Nanjing Jiangbei New Area Biomedical Public Service Platform has already possessed a large number of equipments with higher technical service capacity, which has laid the foundation for the construction of the sub-center." Dr. Kan Suli, Executive Deputy Director of Nanjing Biomedical Subcenter and Chairman of Jiangbei New Area Biomedical Public Service Platform, introduced that over the years of operation, theThe platform has not only invested billions of dollars to equip hardware equipment, but has also formed a service system that runs through the entire process of drug R&D by forming a team to enhance the software.
In addition to hardware support, Nanjing Biomedical Sub-center also strengthens the service guarantee in terms of capital and fund.Make full use of financial instruments such as diversified science and innovation guide funds and science and innovation bonds to support the progress of clinical research in universities and affiliated hospitals, accelerate proof-of-concept as well as small- and medium-sized trial scale-ups, and provide early start-up support funds for the process of moving university projects from the subject group to the industry.
23 university project teams in residence
Receive comprehensive support
On the west side of Xinghuo Road in Jiangbei New District, the Modern Industrial Center of Jiangbei New District, consisting of 11 white buildings, is the operation carrier of Nanjing Biomedical Subcenter.
Since the operation of Nanjing Biomedical Subcenter, there have been good news: China Pharmaceutical University alumni entrepreneurial team's new drug project stationed in Nanjing, Nanjing University of Technology synthetic biology team's project settled, Southeast University organ chip project as the first batch of "creators" stationed ......The sub-center provides these projects with advanced equipment and supporting laboratories and offices, as well as a number of policy supports, including funding, to alleviate the pressure of early project investment.
"The carrier is already available, the project team is doing relevant planning, and it is expected to be officially put into use in a few months." Wu Xiaoyue, the person in charge of the organ chip project promotion team of Southeast University, introduced that Southeast University is one of the earliest colleges and universities in China to engage in organ chip research, and over the past decade or so, it has already produced some landmark technologies and achievements, theThe stationed in Nanjing Biomedical Subcenter, will jointly promote the construction of organ chip technology achievement transformation platform.The platform focuses on the research and development of cutting-edge organ chip technology, application development, achievement transformation and introduction of industrial projects, to create an ecosystem of achievement transformation and industrial innovation in the field of organ chips.
Not only in the province, but the technical managers of Nanjing Biomedical Sub-center also visit the major well-known universities in the country.Currently, 62 universities across the country have been approached, 995 medical achievements have been selected, and 23 projects have been landed.
In the blueprint for the construction of the Nanjing Biomedical Subcenter
Inside the Modern Industrial Center of Jiangbei New District
Four centers will be built
Including exhibition centers, trading centers
Data Center and Roadshow Center
Wu Hao, who is in charge of the operation of the sub-center, introduced, "The exhibition center will comprehensively display the excellent scientific research achievements of universities across the country, and it is not limited to the field of biomedicine; the transaction center will provide technical transaction services for the transfer of scientific research achievements, and relieve the worries of teachers from the universities; the data center will converge all kinds of data, and provide data support for the transfer of the transformation; and the roadshow center will provide a full stage for the good projects of universities to be displayed. The roadshow center will provide a stage for good projects of universities to fully display and dock face-to-face with enterprises and capital."
Three First-Mover Advantages
Creating a "first choice" for transformation
The Regional Technology Transfer and Conversion Center of National Universities has formed an effective model for universities' scientific and technological innovation to comprehensively support industrial innovation by docking with the industrial demands of the country and the region.
For the best universities in the country, with the opportunity to transform the most advanced research results from the university into real-life productivity.The significance of promoting the high-quality development of the city's biomedical industry cannot be overstated.
In Kan Suli's view, Nanjing's development of the biomedical industry, the three major "first" advantage, so that the construction of the Nanjing Biomedical Sub-center has sufficient backing.
- First of all, Nanjing has obvious location advantages.The branch centers are easily accessible, whether they are connecting to colleges and universities in the South or North, or serving businesses across the country;
- Secondly, Nanjing has significant resource advantages.There are many universities, hospitals, and biomedical enterprises, which can provide convenient conditions for "from research to production".
- What's more, biomedicine, as an emerging industry that Nanjing focuses on promoting, has more prominent industrial advantages.Kan Suli said, Nanjing biomedical industry ecology, especially industry cultivation mode, more with the results of the discovery, incubation until the industrialization of the "transformation of the temperament", "Nanjing, a large number of listed companies, unicorn or gazelle enterprises, basically from the source of the beginning of cultivation.Taking Nanjing Biomedical Valley as an example, star enterprises such as Nanwei Medicine, Pharmachem Bio, Shihe Gene, etc., have grown from saplings into big trees.That's why Nanjing has the patience and experience to promote the transfer of scientific research results."
"The construction of the Nanjing Biomedical Subcenter is very crucial for promoting the high-quality development of the biomedical industry in Nanjing and even the whole country." Di Bin, vice president of the Institute of Science and Technology of China Pharmaceutical University, said that with this platform, the government, universities, enterprises and hospitals can be better connected, which is conducive to focusing on the advantages of resources and realizing the synergy to attack major projects.Let Nanjing become the "first choice" for the transformation of biomedical research results of national universities, and make greater contributions to the national innovative drug research and development.
Huang Nan, director of the Institute of Economic Development at the Nanjing Academy of Social Sciences and an expert at the Jiangsu Yangzi River Innovative National City Research Institute, said.As the first leading national innovative city in China, Nanjing has a clear advantage in scientific and technological innovation, and has made important technological breakthroughs in recent years in the fields of biomedicine, artificial intelligence and cyber security.In particular, the construction of the National University Biomedical Regional Technology Transfer and Transformation Center (Nanjing, Jiangsu) is expected to promote the acceleration of the scientific and technological achievements of universities. Turning scientific and technological achievements into real productivity, Nanjing has to further enhance its scientific and technological innovation capacity.
